We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Common Cancer Gene Suppressed

By Biotechdaily staff writers
Posted on 23 May 2005
By studying laboratory mice with skin cancer, scientists have found a way to suppress a mutant gene called Ras, which is found in up to 30% of human tumors.

Ras is a cancer-causing gene, also known as an oncogene; normal copies of this gene are important in the cell-signaling process. More...
However, when mutated, Ras becomes an oncogene and can trigger the growth of tumors in the lung, colon, pancreas, as well as leukemia and thyroid cancer.

Efforts to inhibit activated Ras has had little success to date. However, researchers at the Huntsman Cancer Institute (Salt Lake City, UT, USA) reported that they have found an enzyme that, when inhibited, seems to reduce the incidence of Ras-induced tumors in mice. They published their findings in the May 9, 2005, online early edition of the Journal of the Proceedings of the [U.S.] National Academy of Sciences.

Matthew K. Topham, M.D., assistant professor of internal medicine at the University of Utah School of Medicine (Salt Lake City, UT, USA; www.utah.edu) and lead investigator on the study, explained that the researchers had initially been evaluating a group of enzymes that control the function of the Ras gene. These enzymes, called diacylglycerol kinases (DGKs), are implicated in tumor growth.

"When we began our investigation using a type of DGK, called DGK iota, we thought that its absence would cause more tumors to develop, as has happened with other DGKs we have tested. This time, though, when we tested mice with an activated Ras gene, but an absent DGK iota gene, the number of tumors was significantly reduced,” Dr. Topham remarked. "This result is interesting because it happened when the Ras gene was activated. The implication is that a drug therapy could be developed to reduce tumors caused by Ras without significant side effects.”

The investigators used mice that were bred to have a highly expressed mutant form of the Ras oncogene. Earlier studies showed that these mice were very prone to tumors. For the new study, the group of scientists removed the DGK iota gene in the mice and discovered they developed a small number of tumors, whereas mice with an intact DGK iota gene and an activated Ras gene showed considerably more tumor activity. Dr. Topham said his team will now more closely evaluate the process behind how DGK iota works to inhibit tumor formation.




Related Links:
Huntsman Cancer Institute

New
Gold Member
Aspiration System
VACUSAFE
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Clinical Informatics Platform
CLARION™
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.